MINNEAPOLIS, July 5, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the closing of its previously announced follow-on firm commitment underwritten public offering of 5,200,000 shares of its common stock at a public offering price of $0.75 per share.
